Showing results for IVIG
Developer Workspace
Processing cognitive insights for 'IVIG'...
Treatments for post-vaccine blood clots show promise but no 'slam...
Ever since health officials announced Canada's first known case of rare, post-vaccination blood clots back in April, scientists have been racing to learn more about what causes the potentially deadly ...
Treatments for post-vaccine blood clots show promise but no 'slam...
Ever since health officials announced Canada's first known case of rare, post-vaccination blood clots back in April, scientists have been racing to learn more about what causes the potentially deadly ...
Whole blood transcriptional profiles as a prognostic tool in comp...
Background Early identification of children with Kawasaki Disease (KD) is key for timely initiation of intravenous immunoglobulin (IVIG) therapy. However, the diagnosis of the disease remains challeng...
Whole blood transcriptional profiles as a prognostic tool in comp...
Background Early identification of children with Kawasaki Disease (KD) is key for timely initiation of intravenous immunoglobulin (IVIG) therapy. However, the diagnosis of the disease remains challeng...
Serum lipid metabolites predict the efficacy of intravenous immun...
The response of pediatric dilated cardiomyopathy (PDCM) patients to intravenous immune globulin (IVIG) varies from cardiac functional recovery to heart transplantation and even death. IVIG therapy can...
Aggregates of IVIG or Avastin, but not HSA, modify the response t...
Therapeutic proteins can induce immune responses that affect their safety and efficacy. Product aggregates and innate immune response modulating impurities (IIRMI) are risk factors of product immunoge...
Intravenous immunoglobulin in neurology—mode of action and clinic...
Intravenous immunoglobulin (IVIg), is an effective anti-inflammatory and immunomodulatory treatment for many autoimmune diseases. In this Review, Lünemann and colleagues catalogue the evidence to supp...
The effect of high-dose long-term therapy of intravenous immunogl...
Intravenous Immunoglobulins (IVIG) are used to treat autoimmune autonomic and sensory small fiber neuropathy (ASFN). The long-term effects of a high immunomodulatory dose of IVIG in ASFN remain unclea...
FDA Approves Qivigy for Primary Immunodeficiency Treatment | beyo...
🚀 FDA Approves Kedrion Biopharma’s Qivigy for Primary Humoral Immunodeficiency (PI)
🔹 Approval: Qivigy (10% IVIG, human–kthm) is now FDA-approved for adults with PI.
🔹 Clinical Evidence: CARES10 Pha...
Immunotherapy responsiveness and risk of relapse in Down syndrome...
Down syndrome regression disorder (DSRD) is a clinical symptom cluster consisting of neuropsychiatric regression without an identifiable cause. This study evaluated the clinical effectiveness of IVIg ...
Pharmacogenomics of coronary artery response to intravenous gamma...
Kawasaki disease (KD) is a multisystem inflammatory illness of infants and young children that can result in acute vasculitis. The mechanism of coronary artery aneurysms (CAA) in KD despite intravenou...
Information Literate or Not?: A Nationwide Survey Among Universit...
The Information Education and Information Literacy Working Group (IVIG) was established in 2000. In 2004 and 2005, IVIG conducted a Pilot Survey on the Level of Information Literacy of University Stud...
Defining the risk of first intravenous immunoglobulin unresponsiv...
About 10–20% of patients with Kawasaki disease (KD) are unresponsive to intravenous immunoglobulin (IVIg) and are at increased risk of coronary artery abnormalities (CAAs). Early identification is cri...
Predictive modeling of consecutive intravenous immunoglobulin tre...
Kawasaki disease (KD) is a leading cause of acquired heart disease in children, often resulting in coronary artery complications such as dilation, aneurysms, and stenosis. While intravenous immunoglob...
Impact of 10% vs. 5% immunoglobulin products on treatment outcome...
Kawasaki disease (KD) is an acute vasculitis predominantly affecting younger children, and intravenous immunoglobulin (IVIG) treatment can reduce coronary artery lesion (CAL) development. This multice...
Pharmacogenomics of coronary artery response to intravenous gamma...
Kawasaki disease (KD) is a multisystem inflammatory illness of infants and young children that can result in acute vasculitis. The mechanism of coronary artery aneurysms (CAA) in KD despite intravenou...
Long-term treatment with subcutaneous immunoglobulin in multifoca...
Multifocal motor neuropathy (MMN) is a rare disease with a prevalence of less than 1 per 100,000 people. Intravenous immunoglobulin (IVIG) therapy, performed for a long-term period, has been demonstra...
Defining the risk of first intravenous immunoglobulin unresponsiv...
About 10–20% of patients with Kawasaki disease (KD) are unresponsive to intravenous immunoglobulin (IVIg) and are at increased risk of coronary artery abnormalities (CAAs). Early identification is cri...
The therapeutic window of intravenous immunoglobulin (IVIG) and i...
The optimal therapeutic window to start intravenous immunoglobulin (IVIG) for Kawasaki disease (KD) is highly debatable. We aimed to summarize the existing
Impact of 10% vs. 5% immunoglobulin products on treatment outcome...
Kawasaki disease (KD) is an acute vasculitis predominantly affecting younger children, and intravenous immunoglobulin (IVIG) treatment can reduce coronary artery lesion (CAL) development. This multice...